Xbrane Biopharma AB (XBRANE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has a cash flow conversion efficiency ratio of -0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.50 Million ≈ $-914.74K USD) by net assets (Skr550.16 Million ≈ $59.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XBRANE equity financing ratio to measure how much of total assets are equity-financed.
Xbrane Biopharma AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Xbrane Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Xbrane Biopharma AB cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Xbrane Biopharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xbrane Biopharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JV SPAC Acquisition Corp. Class A Ordinary Share
NASDAQ:JVSA
|
-0.007x |
|
Allied Gaming & Entertainment Inc.
NASDAQ:AGAE
|
0.000x |
|
Oversea Enterprise Bhd
KLSE:0153
|
0.002x |
|
Ucloudlink Group Inc
NASDAQ:UCL
|
-0.337x |
|
Smartlink Holdings Limited
NSE:SMARTLINK
|
0.022x |
|
Maniker
KO:027740
|
-0.041x |
|
Trajan Group Holdings Ltd
AU:TRJ
|
-0.002x |
|
P&H Tech Co. Ltd.
KQ:239890
|
0.059x |
Annual Cash Flow Conversion Efficiency for Xbrane Biopharma AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Xbrane Biopharma AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Xbrane Biopharma AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr560.65 Million ≈ $60.34 Million |
Skr-250.69 Million ≈ $-26.98 Million |
-0.447x | +30.27% |
| 2024-12-31 | Skr208.54 Million ≈ $22.44 Million |
Skr-133.73 Million ≈ $-14.39 Million |
-0.641x | +72.98% |
| 2023-12-31 | Skr171.34 Million ≈ $18.44 Million |
Skr-406.68 Million ≈ $-43.77 Million |
-2.374x | -420.07% |
| 2022-12-31 | Skr424.89 Million ≈ $45.72 Million |
Skr-193.92 Million ≈ $-20.87 Million |
-0.456x | +10.27% |
| 2021-12-31 | Skr431.74 Million ≈ $46.46 Million |
Skr-219.61 Million ≈ $-23.63 Million |
-0.509x | +45.02% |
| 2020-12-31 | Skr257.71 Million ≈ $27.73 Million |
Skr-238.41 Million ≈ $-25.66 Million |
-0.925x | -14.76% |
| 2019-12-31 | Skr184.32 Million ≈ $19.84 Million |
Skr-148.59 Million ≈ $-15.99 Million |
-0.806x | -243.37% |
| 2018-12-31 | Skr83.07 Million ≈ $8.94 Million |
Skr46.71 Million ≈ $5.03 Million |
0.562x | +234.89% |
| 2017-12-31 | Skr88.41 Million ≈ $9.51 Million |
Skr-36.85 Million ≈ $-3.97 Million |
-0.417x | -13.44% |
| 2016-12-31 | Skr107.30 Million ≈ $11.55 Million |
Skr-39.43 Million ≈ $-4.24 Million |
-0.367x | -40.93% |
| 2015-12-31 | Skr47.51 Million ≈ $5.11 Million |
Skr-12.39 Million ≈ $-1.33 Million |
-0.261x | +38.46% |
| 2014-12-31 | Skr6.30 Million ≈ $677.75K |
Skr-2.67 Million ≈ $-287.16K |
-0.424x | -67.55% |
| 2013-12-31 | Skr8.69 Million ≈ $935.17K |
Skr-2.20 Million ≈ $-236.48K |
-0.253x | -- |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adu… Read more